Zhi‐Hui Lin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Zhi‐Hui Lin has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Chang Wu
Department of Cardiology, The Second Affiliated Hospital and Yuying Children's Hospital Wenzhou Medical University Wenzhou China
1 shared publication - Cong Lin
Sun Yat-sen University
1 shared publication - Dongyan Song
Department of Cardiology, the Second Affiliated Hospital and Yuying Children's Hospital Wenzhou Medical University Wenzhou Zhejiang China
1 shared publication - Huaqiang Xiang
Department of Cardiology, The Second Affiliated Hospital and Yuying Children’s Hospital, Wenzhou Medical University, Zhejiang, China
1 shared publication - Kangting Ji
The Second Affiliated Hospital, Yuying Children’s Hospital of Wenzhou Medical University, Wenzhou, China
1 shared publication - Meng‐Qi Wu
Department of Pediatrics, Zhejiang Provincial People's Hospital Center for Reproductive Medicine Hangzhou Zhejiang P.R. China
1 shared publication
Latest Publications
- Open Access
- 27 July 2026
- Published by Wiley in Journal of Biochemical and Molecular Toxicology
- Vol. 40 (8) , e71016
Morroniside Attenuates Doxorubicin‐Induced Cardiotoxicity by Activating the PI3K/AKT/Nrf2/HO‐1 Pathway to Inhibit Ferroptosis and Oxidative Stress
Cardiotoxicity induced by doxorubicin (Dox) significantly contributes to increased mortality among cancer patients, yet available pharmacological interventions remain scarce. Recent studies suggest that ferroptosis is a key mechanism in the development of Dox‐induced cardiotoxicity (DIC). Morroniside (Mor), an active iridoid glycoside isolated from Cornus officinalis , exhibits multiple pharmacological properties such as antioxidant, anti‐ferroptotic, and anti‐inflammatory activities. Given this multi‐target profile, Mor shows potential as a treatment option for reducing DIC. This work was designed to examine the association between Mor and DIC. In vivo DIC model, C57BL/J mice received 5 mg/kg/d Mor via oral gavage for 5 weeks. In vitro DIC model, H9c2 cells were exposed to 10 μM Mor over a 48‐h period. Cardiac injury markers were quantified in serum and cell culture supernatants. Biochemical assays, western blotting, cellular immunofluorescence, and DHE/ROS staining were employed to evaluate ferroptosis and oxidative stress. Mor administration substantially reduced the levels of cardiac injury biomarkers while simultaneously attenuating ferroptosis and oxidative stress in vivo. In cellular models, Mor exhibited potent anti‐ferroptotic and antioxidant effects through Nrf2 pathway activation. Further mechanistic studies identified PI3K/AKT pathway as the upstream regulator of Nrf2 activation in response to Mor treatment. Our study provided the first evidence for Mor's cardioprotective effects against DIC. Mechanistically, Mor attenuated DIC by suppressing ferroptosis and reducing oxidative stress via activation of the PI3K/AKT/Nrf2/HO‐1 signaling pathway.
- 27 July 2026
- Published by Wiley in Journal of Biochemical and Molecular Toxicology
- Vol. 40 (8) , e71016
Open AccessMorroniside Attenuates Doxorubicin‐Induced Cardiotoxicity by Activating the PI3K/AKT/Nrf2/HO‐1 Pathway to Inhibit Ferroptosis and Oxidative Stress
Cardiotoxicity induced by doxorubicin (Dox) significantly contributes to increased mortality among cancer patients, yet available pharmacological interventions remain scarce. Recent studies suggest that ferroptosis is a key mechanism in the development of Dox‐induced cardiotoxicity (DIC). Morroniside (Mor), an active iridoid glycoside isolated from Cornus officinalis , exhibits multiple pharmacological properties such as antioxidant, anti‐ferroptotic, and anti‐inflammatory activities. Given this multi‐target profile, Mor shows potential as a treatment option for reducing DIC. This work was designed to examine the association between Mor and DIC. In vivo DIC model, C57BL/J mice received 5 mg/kg/d Mor via oral gavage for 5 weeks. In vitro DIC model, H9c2 cells were exposed to 10 μM Mor over a 48‐h period. Cardiac injury markers were quantified in serum and cell culture supernatants. Biochemical assays, western blotting, cellular immunofluorescence, and DHE/ROS staining were employed to evaluate ferroptosis and oxidative stress. Mor administration substantially reduced the levels of cardiac injury biomarkers while simultaneously attenuating ferroptosis and oxidative stress in vivo. In cellular models, Mor exhibited potent anti‐ferroptotic and antioxidant effects through Nrf2 pathway activation. Further mechanistic studies identified PI3K/AKT pathway as the upstream regulator of Nrf2 activation in response to Mor treatment. Our study provided the first evidence for Mor's cardioprotective effects against DIC. Mechanistically, Mor attenuated DIC by suppressing ferroptosis and reducing oxidative stress via activation of the PI3K/AKT/Nrf2/HO‐1 signaling pathway.
- 22 May 2024
- Published by Wiley in The FASEB Journal
- Vol. 38 (10) , e23677
Dihydroartemisinin alleviates doxorubicin‐induced cardiotoxicity and ferroptosis by activating Nrf2 and regulating autophagy
Although the use of Doxorubicin (Dox) is extensive in the treatment of malignant tumor, the toxic effects of Dox on the heart can cause myocardial injury. Therefore, it is necessary to find an alternative drug to alleviate the Dox‐induced cardiotoxicity. Dihydroartemisinin (DHA) is a semisynthetic derivative of artemisinin, which is an active ingredient of Artemisia annua. The study investigates the effects of DHA on doxorubicin‐induced cardiotoxicity and ferroptosis, which are related to the activation of Nrf2 and the regulation of autophagy. Different concentrations of DHA were administered by gavage for 4 weeks in mice. H9c2 cells were pretreated with different concentrations of DHA for 24 h in vitro. The mechanism of DHA treatment was explored through echocardiography, biochemical analysis, real‐time quantitative PCR, western blotting analysis, ROS/DHE staining, immunohistochemistry, and immunofluorescence. In vivo, DHA markedly relieved Dox‐induced cardiac dysfunction, attenuated oxidative stress, alleviated cardiomyocyte ferroptosis, activated Nrf2, promoted autophagy, and improved the function of lysosomes. In vitro, DHA attenuated oxidative stress and cardiomyocyte ferroptosis, activated Nrf2, promoted clearance of autophagosomes, and reduced lysosomal destruction. The changes of ferroptosis and Nrf2 depend on selective degradation of keap1 and recovery of lysosome. We found for the first time that DHA could protect the heart from the toxic effects of Dox‐induced cardiotoxicity. In addition, DHA significantly alleviates Dox‐induced ferroptosis through the clearance of autophagosomes, including the selective degradation of keap1 and the recovery of lysosomes.
- 22 May 2024
- Published by Wiley in The FASEB Journal
- Vol. 38 (10) , e23677
Dihydroartemisinin alleviates doxorubicin‐induced cardiotoxicity and ferroptosis by activating Nrf2 and regulating autophagy
Although the use of Doxorubicin (Dox) is extensive in the treatment of malignant tumor, the toxic effects of Dox on the heart can cause myocardial injury. Therefore, it is necessary to find an alternative drug to alleviate the Dox‐induced cardiotoxicity. Dihydroartemisinin (DHA) is a semisynthetic derivative of artemisinin, which is an active ingredient of Artemisia annua. The study investigates the effects of DHA on doxorubicin‐induced cardiotoxicity and ferroptosis, which are related to the activation of Nrf2 and the regulation of autophagy. Different concentrations of DHA were administered by gavage for 4 weeks in mice. H9c2 cells were pretreated with different concentrations of DHA for 24 h in vitro. The mechanism of DHA treatment was explored through echocardiography, biochemical analysis, real‐time quantitative PCR, western blotting analysis, ROS/DHE staining, immunohistochemistry, and immunofluorescence. In vivo, DHA markedly relieved Dox‐induced cardiac dysfunction, attenuated oxidative stress, alleviated cardiomyocyte ferroptosis, activated Nrf2, promoted autophagy, and improved the function of lysosomes. In vitro, DHA attenuated oxidative stress and cardiomyocyte ferroptosis, activated Nrf2, promoted clearance of autophagosomes, and reduced lysosomal destruction. The changes of ferroptosis and Nrf2 depend on selective degradation of keap1 and recovery of lysosome. We found for the first time that DHA could protect the heart from the toxic effects of Dox‐induced cardiotoxicity. In addition, DHA significantly alleviates Dox‐induced ferroptosis through the clearance of autophagosomes, including the selective degradation of keap1 and the recovery of lysosomes.